Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.51 |
| ▸ | CTSK | P43235 | 7/20 | 0.50 |
| ▸ | CTSS | P25774 | 5/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.43 |
| ▸ | XDH | P47989 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 2/20 | 0.42 |
| ▸ | CTSB | P07858 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6129194 | 0.84 | TLR8 (0.45) | TLR8CTSKCTSS | |
| SCHEMBL6618330 | 0.80 | GSK3B (0.44) | TLR8 | |
| Ammonia Solution, Strong SCHEMBL27564785 | 0.79 | GSK3B (0.43) | TLR8 | |
| SCHEMBL7156561 | 0.76 | IDO1 (0.53) | CTSKCTSSIDO1XDHLMNA | |
| Benzylamine SCHEMBL27571278 | 0.75 | TLR8 (0.39) | TLR8 | |
| SCHEMBL13277717 | 0.75 | GSK3B (0.43) | TLR8 | |
| SCHEMBL11297462 | 0.75 | GPR84 (0.44) | TLR8KCNH2 | |
| SCHEMBL2946753 | 0.75 | GPR84 (0.44) | TLR8KCNH2 | |
| SCHEMBL4814536 | 0.72 | GPR84 (0.42) | TLR8KCNH2 | |
| SCHEMBL17626094 | 0.72 | GSK3B (0.41) | LMNAHRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050038087-A1 | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments | IPSEN PHARMA S.A.S. (FR) | 2005-02-17 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038087-A1 | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments | OXER1, OPRL1, OPRK1 | TLR8 1420/4885CTSK 3778/4885CTSS 4183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.